Month: June 2024

The EHE Foundation Attends ASCO 2024

Advancing our Mission, Representing EHE Patients at ASCO 2024

By The EHE Foundation / June 19, 2024 / Comments Off on Advancing our Mission, Representing EHE Patients at ASCO 2024

Our Interim Executive Director and Director of Research, Denise Robinson, recently represented epithelioid hemangioendothelioma (EHE) patients at the 2024 ASCO Annual Meeting in Chicago, Illinois, where nearly 40,000 global oncology professionals convened. The American Society of Clinical Oncology (ASCO), is the world’s leading organization for oncology, bringing together advocates, healthcare providers, and related professionals to […]

Read More
2024 EHE Fun Run & Walk Recap

Reflecting on Success: 2024 EHE Fun Run & Walk Recap

By The EHE Foundation / June 18, 2024 / Comments Off on Reflecting on Success: 2024 EHE Fun Run & Walk Recap

With enthusiasm and gratitude, The EHE Foundation is proud to celebrate another successful year of the Annual EHE Fun Run & Walk. This event, dedicated to supporting The EHE Foundation’s mission to find treatments and a cure for epithelioid hemangioendothelioma (EHE), always brings our community together in an extraordinary way! With 1387 registrations, our hearts […]

Read More
EHE community donations expand grant.

Planting Seeds for Future Developments: EHEF Research Grant Grows

By The EHE Foundation / June 14, 2024 / Comments Off on Planting Seeds for Future Developments: EHEF Research Grant Grows

The EHE Foundation invests in novel EHE research yearly through its EHE Research Grants Program. The program officially began in 2021, with only a few applicants interested in EHE research. Today, 10 applicants have submitted proposals in our 2024 grants cycle.  Along the way, we have had the good fortune to meet and collaborate with […]

Read More
Ikena Oncology's IK-930 Trial Discontinued

Ikena Oncology IK-930 Update

By The EHE Foundation / June 7, 2024 / Comments Off on Ikena Oncology IK-930 Update

On May 28, 2024, Ikena Oncology announced they are discontinuing the development of IK-930. We share your frustration and disappointment and understand the devastating impact felt by patients. Following this announcement, we met with Ikena to impress upon them the urgency and importance that patients deriving benefits from IK-930 continue to have access to the […]

Read More